Angiex is a company headquartered in the United States. Brouky records 1 investor associated with the company.
Angiex develops Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) to create targeted therapies for solid tumors by delivering chemotherapeutic agents directly to the nucleus of tumor and tumor blood vessel cells.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.